Lucid Diagnostics Inc. (NASDAQ:LUCD) Receives $3.94 Consensus Price Target from Brokerages

by · The Cerbat Gem

Shares of Lucid Diagnostics Inc. (NASDAQ:LUCD – Get Free Report) have received an average rating of “Moderate Buy” from the five brokerages that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $3.9375.

A number of brokerages have recently commented on LUCD. Ascendiant Capital Markets increased their price target on Lucid Diagnostics from $8.00 to $8.25 and gave the company a “buy” rating in a research note on Wednesday, December 10th. Wall Street Zen cut Lucid Diagnostics from a “hold” rating to a “sell” rating in a report on Saturday, November 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Lucid Diagnostics in a research note on Monday, December 29th. Finally, Needham & Company LLC restated a “buy” rating and set a $3.00 price target on shares of Lucid Diagnostics in a report on Thursday, November 13th.

Get Our Latest Analysis on Lucid Diagnostics

Hedge Funds Weigh In On Lucid Diagnostics

Several large investors have recently modified their holdings of LUCD. Two Seas Capital LP acquired a new position in shares of Lucid Diagnostics during the third quarter worth $3,030,000. Ghisallo Capital Management LLC bought a new position in Lucid Diagnostics during the 3rd quarter worth $2,990,000. Aberdeen Group plc acquired a new position in Lucid Diagnostics during the 3rd quarter worth about $2,525,000. Geode Capital Management LLC grew its position in shares of Lucid Diagnostics by 420.3% in the 2nd quarter. Geode Capital Management LLC now owns 1,577,369 shares of the company’s stock valued at $1,814,000 after buying an additional 1,274,194 shares during the last quarter. Finally, Masters Capital Management LLC grew its position in shares of Lucid Diagnostics by 46.6% in the 3rd quarter. Masters Capital Management LLC now owns 3,999,273 shares of the company’s stock valued at $4,039,000 after buying an additional 1,272,000 shares during the last quarter. Institutional investors own 74.01% of the company’s stock.

Lucid Diagnostics Trading Down 4.1%

LUCD opened at $1.18 on Thursday. The company has a market cap of $162.46 million, a P/E ratio of -1.13 and a beta of 1.22. The company’s 50 day moving average is $1.09 and its 200-day moving average is $1.11. Lucid Diagnostics has a 1-year low of $0.80 and a 1-year high of $1.80.

Lucid Diagnostics (NASDAQ:LUCD – Get Free Report) last released its quarterly earnings data on Wednesday, November 12th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.04). The company had revenue of $1.21 million for the quarter, compared to analyst estimates of $1.35 million. On average, equities analysts forecast that Lucid Diagnostics will post -0.84 EPS for the current year.

Lucid Diagnostics Company Profile

(Get Free Report)

Lucid Diagnostics is a molecular diagnostics company focused on improving early detection of oral and oropharyngeal cancers. The company’s flagship offering, the LucidDx Oral Cytology Brush Test, combines a minimally invasive brush biopsy tool with proprietary laboratory analysis to identify cellular abnormalities indicative of malignancy. Samples collected in dental and medical offices are sent to Lucid’s CLIA-certified and CAP-accredited laboratory, where advanced imaging and cytopathology workflows generate diagnostic reports for clinicians and patients.

Since commencing commercial operations, Lucid Diagnostics has worked to integrate its testing platform into dental practices, oral surgery clinics and ENT specialists across the United States.

Further Reading